Fluoroquinolones are potent antibacterial agents being used clinically against multidrug-resistant tuberculosis. Treatment failure is thought to arise from acquisition of fluoroquinolone resistance by Mycobacterium tuberculosis. A collection of 13 resistant clinical isolates of M. tuberculosis was examined for ciprofloxacin sensitivity relative to controls exhibiting the same IS6110 DNA type. Specific alleleswere associated with distinct levelsof drug susceptibility for 11 isolates that contained nucleotide changes expected to alter the amino acid sequence of the A subunit of DNA gyrase. Five different gyrA (ciprofloxacin resistance) alleles were present among 7 isolates having the W DNA subtype. These isolates, which are representative of an outbreak strain, constitute a panel of organisms that can be used to evaluate contributions of gyrase and DNA topoisomerase IV to resistance.
During the last decade, tuberculosis has resurfaced as a public health problem in developed countries, and associated with the increased incidence of disease has been a striking frequency of resistance to the primary antituberculosis agents (14% of New York City cases in 1992 [I] ). When treatment failures occurred, alternative antibiotics were administered that sometimes failed to cure the disease due to the organism's acquisition of resistance to additional antibiotics. Some Mycobacterium tuberculosis isolates are now resistant to as many as nine different agents. Often the patients were also infected with human immunodeficiency virus type I [2, 3] . The widespread distribution of M. tuberculosis, coupled with the rapid spread of human immunodeficiency virus type I infection, poor patient adherence, and inadequate administration of antibiotics, makes it likely that multidrug-resistant tuberculosis will become an increasingly serious therapeutic problem.
In an effort to develop more effective antimicrobial agents, we have been studying the fluoroquinolones. A principal target of these agents is thought to be DNA gyrase, the enzyme responsible for controlling negative supercoiling in bacterial DNA (reviewed in [4] [5] [6] ). During the supercoiling reaction, gyrase transiently breaks duplex DNA, and the fluoroquinolone traps a reaction intermediate containing broken DNA. That process leads to cell death when the DNA breaks are released from gyrase-mediated constraint [7] . Two fluoroquinolones, ciprofloxacin and ofioxacin, are currently used as antituberculosis agents (reviewed in [8] ). Mycobacterial resistance to these drugs has been associated with point mutations clustering around alanine-90 in the amino-terminal portion of GyrA [9] , one of the two gyrase subunits. In other bacteria, fiuoroquinolone resistance is also attributed to mutations in gyrA and in some cases to mutations in gyrB, nor.A, and pare [5, 7, 10] . Preliminary work [9] suggested that specific gyrA mutations might be associated with distinct levels of fluoroquinolone susceptibility in M. tuberculosis. To test this idea, we examined ciprofloxacin-resistant clinical isolates [2] , many of which shared a recent common ancestor.
Materials and Methods
Isolates of M. tuberculosis were part of a collection maintained at the Public Health Research Institute Tuberculosis Center, New York City. Susceptibilities to isoniazid (0.2 p,g/mL), rifampin (2 p,g/mL), streptomycin (6 p,g/mL), and ethambutol (7.5 p,g/mL) were usually determined by the BACTEC (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD) radiorespiratory method. Some isolates were tested by the proportion method using Middlebrook 7HlO agar (Difco, Detroit) with the following drug concentrations: isoniazid (l p,g/mL), rifampin (l p,g/mL), streptomycin (2 and 10 p,g/mL), and ethambutol (5 p,g/mL). The isolates in the present study were also tested with ethionamide (7.5 J.lg/mL), kanamycin (5 p,g/mL), ciprofioxacin (2 p,g/mL), chloramphenicol (10 J.lg/mL), and cycloserine (30 p,g/mL)by the proportion method.
Quantitative estimates of fiuoroquinolone susceptibility were made by determining the antibiotic concentration required to inhibit growth in liquid culture by 50% (ID so ). Measurement of the ID so provided the same information as the MIC so , but ID so determination was logistically simpler and less expensive. Moreover, it required much less incubator space, an important consideration for work in biosafety level 3 containment facilities.
For ID so measurements, cells were first grown as isolated colonies on Middlebrook 7HlO agar with incubation at 37°C in the presence of CO 2 , Individual colonies were then transferred to Middlebrook 7H10 liquid medium in stationary tubes for growth of starter cultures, and turbidity (A S40 ) was determined periodically as a measure of culture growth. When culture turbidity reached 0.3-0.4, aliquots were diluted lO-fold from starter cultures into a series of tubes containing various concentrations of ciprofioxacin * IS6110 DNA pattern as described in [IIJ.
t Isolates were resistant to indicated antibiotics: I, isoniazid; S, streptomycin; R, rifampicin; Em, ethambutol; C, ciprofloxacin; Kn, kanamycin; Et, ethionamide; Cm, chloramphenicol; and Pz, pyrazinamide.
t Nos. and letters indicate mutant amino acids of GyrA with first letter representing wild type (wt) followed by codon number and letter representing amino acid in mutant.
Ciprofloxacin concentration required to block growth by 50%, determined as in figure I (average of at least 3 independent determinations z: SD of mean).
II Relative to wild type having same 1S611O pattern.
(Bayer, Kankakee, IL) or sparfloxacin (Parke-Davis Pharmaceutical, Ann Arbor, MI). Cultures were continuously agitated by being horizontally rolled inside a plastic bottle (Low Profile Roller; Stovall Life Sciences, Greensboro, NC). After~10 days, culture turbidity stopped increasing, and at that point, plots of growth as a function of ciprofloxacin concentration were prepared. As a check for contamination, each starter culture was also diluted into a tube containing LB medium and incubated with the antibiotic. For each isolate, fluoroquinolone susceptibility was determined from at least 3 individual colonies to monitor possible culture heterogeneity. Work with living bacteria was done in a biosafety level 3 facility. DNA was extracted from cells that were grown on Middlebrook 7HlO agar and then resuspended in Middlebrook 7H9 medium as described in [11] . DNA typing was based on the observation that M. tuberculosis isolates vary in number and chromosomal location of insertion element IS6110 [11, 12] . A 350-bp region containing the fIuoroquinolone-resistance region of gyrA was amplified using the polymerase chain reaction with primers described previously [9] ; automated DNA sequence analysis was done as described previously [13] .
Results
As part of a clinical study, ciprofloxacin-resistant isolates of M. tuberculosis, defined by growth on agar containing 2 f..Lgl mL ciprofloxacin, were collected and examined for nucleotide sequence changes [2, 13] . Many isolates showed changes in the quinolone-resistance region of gyrA. Properties of isolates that could be recovered from storage, plus 5 new resistant isolates, are listed in table 1. IS6110 DNA typing revealed that 7 of these isolates were of the W type, a group sharing a recent common ancestor [2, 12] ; DNA sequencing showed that all ciprofloxacin-resistant W isolates had a gyrA mutation. As pointed out previously [2] , the diversity of gyrA mutations supports the idea that members of a spreading, multidrug-resistant strain can independently acquire a variety of resistance alleles. The availability of IS 6110 information for sensitive and resistant isolates made it feasible to ask whether correlations exist between specific gyrA mutations and the level of susceptibility.
Cultures were diluted into liquid medium containing various concentrations of ciprofloxacin, and culture turbidity was monitored as an indicator of growth. An example is shown in figure  1 , in which M. tuberculosis isolates were obtained from the same patient before (isolate TN1626) and after (isolate TN1627) ciprofloxacin therapy. In this case, a mutation in codon 94 of GyrA, which converted aspartic acid to tyrosine, Conversion of aspartic acid to glycine at position 94 (isolates TN755 and TN606) was associated with the greatest reduction in susceptibility, showing a 60-fold difference relative to a ciprofloxacin-sensitive W isolate (TN 1626). Examination of the effects of sparfloxacin on W isolates TN1626, TN1627, and TN606 showed the same rank order of susceptibility observed with ciprofloxacin (data not shown). Several other isolates had 1S6110 DNA patterns arbitrarily named H, DV, CO, and P [12] . The H, DV, and CO isolates were represented by different gyrA alleles and had 1D so values about twice that ofW-type strains having the same gyrA alleles (table 1). Since ciprofloxacin-sensitive H, DV, and CO isolates were also less susceptible than a drug-sensitive W isolate, the contribution of specific gyrA alleles to resistance may be similar among isolates, although such a conclusion must remain tentative until isogenic strains are tested. The relative ID so for strain TN2813 may be anomalously low due to the high ID so of the control strain TN3541. Members of the P group exhibited a level of resistance similar to that observed for mutation at codon 90 for the W-type isolate. The P isolates were unusual because they lacked an identifiable mutation in the fluoroquinolone-resistance region of gyrA. A mutation associated with fluoroquinolone resistance in the P isolates has not been identified.
An additional polymorphism was detected at position 95. In types W, H, DV, and P, amino acid 95 was threonine, while it was serine for CO isolates. There was no simple relationship between this polymorphism and ciprofloxacin susceptibility in this data set or in >600 additional isolates recovered from global sources (Musser JM, unpublished observations).
Discussion
Isolates of the W IS6110 DNA type represent an outbreak strain of multidrug-resistant M. tuberculosis that very recently spread throughout New York City and elsewhere [12] , a conclusion that is strongly supported by the isolates having identical mutations in the genes responsible for resistance to three first-line antibiotics, isoniazid, rifampin, and streptomycin [12] . The gyrA mutations associated with ciprofloxacin resistance (table 1) probably arose after widespread dispersal of the strain, since a variety of alleles was observed.
The availability of a set of clinical isolates of M. tuberculosis that share a common ancestor [12] made it possible to correlate specific mutations in the fluoroquinolone-resistance region of gyrA with particular levels of ciprofloxacin susceptibility (table  I) . The alanine-to-valine mutation at codon 90 was associated with a 16-fold decrease in susceptibility, and mutations changing an aspartic acid at position 94 to either histidine, asparagine, or tyrosine were associated with a 30-fold decrease in susceptibility. An additional2-fold reduction in susceptibility was associated with the aspartic acid-to-glycine change at position 94. Mutation position effects have been observed with other quinolones tested against Escherichia coli [14] . However, with E. coli the highest level of resistance arose from changes in the position equivalent to amino acid 90 of M tuberculosis rather than in the one equivalent to position 94 [14] . Evidence is accumulating that mutations in other genes can contribute to reduced susceptibility, as reflected in ID so [7, 10, 15] , although association of M. tuberculosis resistance with mutations in genes other than gyrA has not been demonstrated. Once the nucleotide sequence of genes encoding topoisomerase IV is known, the panel of isolates listed in table I will make it possible to determine whether a mutation in those genes correlates with decreased susceptibility to ciprofloxacin.
Data obtained with ciprofloxacin-resistant isolates exhibiting the H or CO IS6110 DNA patterns were similar to determinations made with the W-type isolates. With the DV type, the difference in ciprofloxacin susceptibility between sensitive and resistant isolates was less than that for the same gyrA allele with W-type isolates. Additional DV isolates will be tested when they become available to assess the generality of the DV data.
The P-type isolates are interesting because they lacked a mutation in the quinolone-resistance region of gyrA. Since we did not examine the entire gyrA gene, a mutation may reside in another part of gyrA, as has been found with other bacteria [5] . It is also possible that one or more mutations arose in gyrB, parC, or norA, other genes to which quinolone resistance has been mapped. Additional experiments are necessary to address this issue.
The present study has two practical implications. First, the vast majority (11/13) of resistance-conferring mutations mapped in the quinolone-resistance-determining region of gyrA. Thus, nucleotide sequence determination following polymerase chain reaction-based amplification could be used to identify ciprofloxacin-resistant strains, once it is established by sequence analysis that no other gyrA mutation is present and by genetic complementation that gyrA mutations are required for resistance. Strains sensitive to ciprofloxacin do not contain the mutations listed in table 1 (>600 have been examined to date [Musser 1M, unpublished observationsD. Second, the Wtype fluoroquino1one-resistant isolates provide a panel of organisms that can be used to test new fluoroquinolones for activity against nongyrase targets such as topoisomerase IV [7, 10] . Since fluoroquinolone-resistance mutations arise readily in clinical settings (reviewed in [8D, superior compounds might be those that are especially effective against both gyrase and topoisomerase IV, since then two mutations would be required to confer clinical resistance. In preliminary studies, we have found that sparfloxacin is four times as effective as ciprofloxacin against resistant mutants (TN 1627 and TN606) but only twice as effective against a sensitive isolate (TN 1626). We are now using the panel of isolates to test other fluoroquinolones for an even more exaggerated effect against gyrA mutants.
